title: PulmonaryMycobacterium kansasiidisease in immunocompetent host: Treatment outcomes with short-course chemotherapy.
abstract: Mycobacterium kansasii, most virulent of all atypical mycobacteria, causes pulmonary disease identical to the disease caused by Mycobacterium tuberculosis. Early identification of the species and prompt initiation of treatment for M. kansasii is necessary to prevent morbidity and mortality due to this disease. This case series highlights the similarity in the clinical presentation of both M. tuberculosis and M. kansasii and response to direct observation of short-course chemotherapy with rifampicin, in the management of pulmonary M. kansasii disease. Larger studies are required to evaluate the long-term effect of short-course chemotherapy, especially use of moxifloxacin, in the management of pulmonary M. kansasii disease.
authors.affiliation: Department of Clinical Research, National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.
authors.forename: C
authors.initials: C
authors.lastname: Padmapriyadarsini
authors.affiliation: Department of Clinical Research, National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.
authors.forename: D
authors.initials: D
authors.lastname: Nair
authors.affiliation: Department of Bacteriology, National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.
authors.forename: N S
authors.initials: NS
authors.lastname: Gomathi
authors.affiliation: Department of Clinical Research, National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.
authors.forename: B
authors.initials: B
authors.lastname: Velayudham
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology* / Q000473:pathology; D019909:Mycobacterium kansasii / Q000302:isolation & purification*; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology* / Q000473:pathology; D012293:Rifampin / Q000627:therapeutic use; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000382:microbiology / Q000473:pathology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077266:Moxifloxacin; D012293:Rifampin